The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 09, 2018
Filed:
Dec. 16, 2013
Universitaetsmedizin Der Johannes Gutenberg-universitaet Mainz, Mainz, DE;
Universitaet Duisberg-essen, Essen, DE;
Dirk Schadendorf, Essen, DE;
Annette Paschen, Essen, DE;
Silke Luebcke, Mainz, DE;
Martina Fatho, Woerrstadt, DE;
Daniela Eberts, Finthen, DE;
Hakim Echchannaoui, Mainz, DE;
Volker Lennerz, Ober-Olm, DE;
Catherine Woelfel, Mainz, DE;
Thomas Woelfel, Mainz, DE;
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, DE;
Universitaet Duisburg-Essen, Essen, DE;
Abstract
The present invention relates to novel tumor-associated antigens, which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention. The invention further pertains to pharmaceutical compositions, especially vaccine compositions, comprising the antigens, nucleic acids, binding agents or T cells in accordance with the invention, and methods for the generation of T cells, which are specifically reactive to the antigens of the invention in an MHC-independent manner.